Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Allakos Inc (ALLK)
NASDAQ:ALLK
Holding ALLK?
Track your performance easily
ALLK Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.54 - $3.41
Previous Close$1.35
Volume279.74K
Average Volume (3M)612.37K
Market Cap
$120.61M
Enterprise Value$63.61M
Total Cash (Recent Filing)$92.72M
Total Debt (Recent Filing)$35.71M
Price to Earnings (P/E)―
Beta1.54
Next Earnings
Mar 04, 2025EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.03
Shares Outstanding89,343,634
10 Day Avg. Volume726,361
30 Day Avg. Volume612,370
Standard Deviation0.27
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.42
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.36
Forecast
1Y Price Target
$3.25Price Target Upside140.74% Upside
Rating ConsensusHold
Number of Analyst Covering6
Allakos News
PremiumCompany Announcements
Allakos Progress Update on AK006 and Future Milestones
PremiumCompany Announcements
Allakos Reveals New Corporate Strategy and Performance InsightsBulls Say, Bears Say
Bulls Say
Clinical DataEnthusiasm for AK006 is expected to build as incremental clinical data is gathered, with key data from CSU patients providing a major catalyst for ALKK shares.
Receptor OccupancyPhase 1 data confirmed AK006 reaches the pathogenic cell type (mast cells) in the target tissue (skin) with receptor occupancy levels (>90%) that exceed levels associated with potent inhibition in preclinical models (~70%).
Safety And EfficacyThe safety profile of subcutaneous AK006 up to 720mg appeared safe and well-tolerated with no serious adverse events or dose-limiting toxicities.
Bears Say
Clinical DataThe lack of pharmacodynamic data was the likely cause for ALLK trading down following this update.
Data AvailabilityNot enough sample for ex-vivo mast cell pharmacodynamic analysis suggests challenges in data collection.
Market ConfidenceStrong proof-of-concept data is seen as key to restoring confidence in ALLK's CSU development program, following the recent clinical setbacks for lirentelimab in atopic dermatitis and CSU.
---
Ownership Overview
9.73% Insiders
10.94% Mutual Funds
0.03% Other Institutional Investors
74.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLK FAQ
What was Allakos Inc’s price range in the past 12 months?
Allakos Inc lowest stock price was $0.54 and its highest was $3.40 in the past 12 months.
What is Allakos Inc’s market cap?
Currently, no data Available
When is Allakos Inc’s upcoming earnings report date?
Allakos Inc’s upcoming earnings report date is Mar 04, 2025 which is in 116 days.
How were Allakos Inc’s earnings last quarter?
Allakos Inc released its earnings results on Nov 06, 2024. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.248 by $0.038.
Is Allakos Inc overvalued?
According to Wall Street analysts Allakos Inc’s price is currently Undervalued.
Does Allakos Inc pay dividends?
Allakos Inc does not currently pay dividends.
What is Allakos Inc’s EPS estimate?
Allakos Inc’s EPS estimate is -$0.21.
How many shares outstanding does Allakos Inc have?
Allakos Inc has 89,343,636 shares outstanding.
What happened to Allakos Inc’s price movement after its last earnings report?
Allakos Inc reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.248. Following the earnings report the stock price went down -4.255%.
Which hedge fund is a major shareholder of Allakos Inc?
Among the largest hedge funds holding Allakos Inc’s share is Platinum Investment Management. It holds Allakos Inc’s shares valued at 1M.
---
Allakos Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.25 (140.74% Upside)
$3.25 (140.74% Upside)
Blogger Sentiment
Bearish
ALLK Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 233.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-34.62%
12-Months-Change
Fundamentals
Return on Equity
-121.68%
Trailing 12-Months
Asset Growth
-56.11%
Trailing 12-Months
Company Description
Allakos Inc
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
---
ALLK Stock 12 Month Forecast
Average Price Target
$3.25
▲(140.74% Upside)
Technical Analysis
Best Analysts Covering ALLK
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+50.36%
upgraded a buy rating 11 months ago
Copying Tim Lugo's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +50.36% per trade.
---